
-
Pyxis Oncology NASDAQ:PYXS Pyxis Oncology, Inc. is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies.
Location: | Website: pyxisoncology.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-48.16M
Cash
144.8M
Avg Qtr Burn
-13.41M
Short % of Float
17.85%
Insider Ownership
24.57%
Institutional Own.
41.52%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PYX-201 + Pembrolizumab Details Solid tumor/s | Phase 1/2 Initiation | |
PYX-201 Details Head and neck cancer, Breast cancer, Thyroid cancer, Lung cancer | Phase 1 Data readout | |
PYX-106 Details Colorectal cancer , Kidney cancer, Bladder cancer, Cholangiocarcinoma | Failed Discontinued |